

Supplemental Table 1: Distribution of the inhabitants of the county of Tirschenreuth and of the study participants (n = 64 643 of inhabitants of Tirschenreuth county aged ≥ 14 years and 4 203 study participants, respectively).

	Number of inhabitants in the county	% (among county inhabitants aged ≥ 14 years)	Number of study participants	% (among study participants)	absolute deviation between study and county (%)
Gender analysis					
men	32239	49.87	2032	48.35	-1.52
women	32404	50.13	2171	51.65	1.52
Age group analysis					
14 - 19	3994	6.17	227	5.40	-0.77
20 - 29	8146	12.58	523	12.44	-0.14
30 - 39	8430	13.18	585	13.92	0.74
40 - 49	8782	13.56	601	14.30	0.74
50 - 59	12813	19.79	882	20.99	1.20
60 - 69	10412	16.08	752	17.89	1.81
70 - 74	3422	5.29	232	5.52	0.23
75 - 79	3350	5.17	192	4.57	-0.60
80 - 84	3412	5.27	161	3.83	-1.44
≥ 85	1882	2.91	48	1.14	-1.77
Municipality analysis					
Bad Neualbenreuth	1186	1.83	93	2.21	0.38
Bärnau	2795	4.32	189	4.50	0.18
Brand	1025	1.58	59	1.40	-0.18
Ebnath	1710	2.65	65	1.55	-1.10
Erbendorf	4476	6.91	263	6.26	-0.65
Falkenberg	822	1.27	73	1.74	0.47
Friedenfels	1103	1.70	87	2.07	0.37
Fuchsmühl	1387	2.14	87	2.07	-0.07
Immenreuth	1600	2.47	100	2.38	-0.09
Kastl	1208	1.87	83	1.97	0.10
Kemnath	4773	7.37	294	7.00	-0.37
Konnersreuth	1501	2.31	109	2.59	0.28
Krummennaab	1299	2.01	85	2.02	0.01
Kulmain	1928	2.98	136	3.24	0.26
Leonberg	870	1.34	69	1.64	0.30
Mähring	1560	2.41	107	2.55	0.14
Mitterteich	5899	9.11	376	8.95	-0.16
Neusorg	1810	2.80	131	3.12	0.32
Pechbrunn	1173	1.81	72	1.71	-0.10
Plößberg	2835	4.38	206	4.90	0.52
Pullenreuth	1500	2.32	110	2.62	0.30
Reuth b.Erbendorf	994	1.54	71	1.69	0.15
Tirschenreuth	7807	12.06	547	13.01	0.95
Waldershof	3869	5.98	205	4.88	-1.10
Waldsassen	5862	9.05	356	8.47	-0.58
Wiesau	3651	5.64	230	5.47	-0.17

Supplemental Table 2. Seroprevalence (SP), dark figure (DF) factor and infection fatality ratio (IFR) in the study population and standardized to the population of the county Tirschenreuth

Group	SP (%)	SP (%) 95%-CI ⁶	PCR + ² (%)	DF ³ factor	DF ³ factor 95%-CI ⁷	IFR ⁴ (%)	IFR ⁴ (%) 95%-CI ⁷
overall							
crude	8.641	7.828 - 9.529					
standardized ¹	8.571	7.768 - 9.449	1.710	5.013	4.462 - 5.587	2.487	2.058 - 3.022
men							
crude	8.567	7.427 - 9.864					
standardized ²	8.500	7.373 - 9.783	1.434	5.928	4.978 - 6.939	2.806	2.171 - 3.669
women							
crude	8.710	7.595 - 9.970					
standardized ²	8.641	7.540 - 9.888	1.984	4.355	3.707 - 5.038	2.175	1.648 - 2.903

¹ Standardized according to age, gender and municipality

² Standardized according to age and municipality

³ Registered PCR positive (%) by local health authorities

⁴ Dark figure factor: Ratio of standardized seroprevalence (%) and registered positive PCR (%), respectively.

⁵ IFR (%): Infection fatality ratio. Percentage of people who have died from or with CoV-2 infection relative to the calculated number of seropositive individuals

⁶Confidence intervals (CI) were estimated according to Wilson-Score-Method

⁷Confidence intervals (CI) were computed as Bayesian credibility intervals (see methods)

Supplemental Table 3. Age-specific seroprevalence (SP), dark figure (DF) factor and infection fatality ratio (IFR) in the study cohort and standardized according to the gender and local municipality distribution of the population of the county Tirschenreuth

Age group	SP (%) ¹	SP(%) ¹ ; 95%-CI ⁵	SP (%) ²	SP(%) ² ; 95%-CI ⁵	Registered positive PCR (# and (%))	DF ³ factor	DF ³ factor; 95%-CI ⁶	Number of deaths	IFR ⁴ (%)	IFR ⁴ (%); 95%-CI ⁶
14-19	10.177	6.878 - 14.808	10.039	6.818 - 14.595	33 (0.826)	12.154	6.749 - 19.322	0	0	0.000 - 0.993
20-29	8.795	6.659 - 11.533	8.676	6.588 - 11.367	98 (1.203)	7.212	4.975 - 9.811	1	0.141	0.034 - 0.823
30-39	6.154	4.478 - 8.402	6.070	4.433 - 8.828	105 (1.231)	4.931	3.258 - 6.845	0	0	0.000 - 0.749
40-49	9.651	7.540 - 12.274	9.519	7.455 - 12.098	147 (1.674)	5.687	4.147 - 7.424	0	0	0.000 - 0.452
50-59	9.989	8.179 - 12.146	9.853	8.083 - 11.972	217 (1.694)	5.818	4.522 - 7.247	5	0.396	0.172 - 0.956
60-69	7.979	6.249 - 10.136	7.871	6.179 - 9.990	141 (1.354)	5.812	4.244 - 7.593	8	0.976	0.489 - 2.038
70-74	9.052	5.997 - 13.441	8.929	5.948 - 13.248	65 (1.899)	4.701	2.678 - 7.089	13	4.255	2.289 - 8.961
75-79	5.208	2.853 - 9.321	5.138	2.847 - 9.189	75 (2.239)	2.295	1.016 - 3.837	19	11.040	5.836 - 30.210
80-84	9.938	6.210 - 15.533	9.803	6.168 - 15.312	110 (3.224)	3.041	1.605 - 4.622	31	9.268	5.563 - 18.820
85+	10.417	4.532 - 22.168	10.275	4.564 - 21.874	116 (6.164)	1.667	1.001 - 3.119	61	31.545	16.437 - 99.046

¹Crude data as observed in the study population

²Standardized according to gender and municipality

³Dark figure - factor: Ratio of standardized seroprevalence (%) and registered positive PCR (%), respectively.

⁴IFR (%): Infection fatality ratio. Percentage of people who have died from or with SARS-CoV-2 infection relative to the calculated number of standardized seropositive individuals

⁵Confidence intervals (CI) were estimated according to Wilson-Score-Method

⁶Confidence intervals (CI) were computed as Bayesian credibility intervals (see methods)

Supplemental Table 4. Local seroprevalence (SP) in the study cohort and standardized according to the age and gender distribution of the population of the county Tirschenreuth

Local Municipality	SP (%) ¹	SP (%) ¹ 95%-CI ³	SP (%) ²	SP (%) ² 95%-CI ³
Bad Neualbenreuth	7.527	3.694 - 14.730	7.567	3.691 - 14.809
Brand	5.085	1.744 - 13.917	5.111	1.726 - 13.986
Bärnau	8.466	5.278 - 13.308	8.510	5.291 - 13.382
Ebnath	4.615	1.582 - 12.714	4.640	1.565 - 12.777
Erbendorf	7.634	4.996 - 11.496	7.674	5.011 - 11.561
Falkenberg	2.740	0.755 - 9.450	2.754	0.738 - 9.495
Friedenfels	5.747	2.480 - 12.758	5.778	2.471 - 12.824
Fuchsmühl	12.644	7.209 - 21.238	12.711	7.221 - 21.354
Immenreuth	1.000	0.177 - 5.449	1.005	0.164 - 5.471
Kastl	2.410	0.663 - 8.366	2.422	0.648 - 8.406
Kemnath	1.701	0.729 - 3.919	1.710	0.726 - 3.940
Konnnersreuth	11.927	7.104 - 19.342	11.990	7.120 - 19.448
Krummennaab	10.588	5.671 - 18.914	10.644	5.676 - 19.016
Kulmain	5.147	2.515 - 10.243	5.174	2.513 - 10.299
Leonberg	18.841	11.355 - 29.613	18.940	11.384 - 29.773
Mitterteich	18.351	14.765 - 22.577	18.448	14.833 - 22.702
Mähring	16.822	10.914 - 25.031	16.911	10.949 - 25.168
Neusorg	6.107	3.127 - 11.588	6.139	3.126 - 11.651
Pechbrunn	12.500	6.718 - 22.081	12.566	6.724 - 22.200
Plößberg	6.341	3.743 - 10.546	6.375	3.750 - 10.605
Pullenreuth	3.636	1.423 - 8.979	3.656	1.414 - 9.025
Reuth b.Erbendorf	22.535	14.375 - 33.515	22.654	14.420 - 33.696
Tirschenreuth	9.506	7.323 - 12.254	9.557	7.354 - 12.323
Waldershof	3.902	1.990 - 7.510	3.923	1.990 - 7.551
Waldsassen	8.427	5.966 - 11.775	8.472	5.988 - 11.841
Wiesau	8.261	5.352 - 12.541	8.305	5.368 - 12.611

¹Crude data as observed in the study population

²Standardised according to gender and age

³Confidence intervals (CI) were estimated according to Wilson-Score-Method.

Supplemental table 5: Seroprevalence (SP), dark figure (DF) factor and infection fatality ratio (IFR) in municipality subgroups with and without senior citizen residences in the county of Tirschenreuth

Municipality subgroup	# in county # in study # seropositives	SP (%) ¹ 95%-CI ⁴	Registered positive PCR #, %	DF ² 95%-CI ⁵	Number of deaths	IFR (%) ³ 95%-CI ⁵
with senior citizen residences	43870 2802 248	8.898 7.893 - 10.014	888 2.024	4.083 3.828 - 4.989	125	3.202 2.609 - 3.967
without senior citizen residences	20773 1399 115	8.264 6.925- 9.831	219 1.049	8.482 6.279 - 9.656	13	0.754 0.436 - 1.334

¹Standardised according to gender and age

²Dark figure factor: Ratio of standardized seroprevalence (%) and registered positive PCR (%), respectively.

³IFR (%): Infection fatality ratio. Percentage of people who have died from or with CoV-2 infection relative to the calculated number of standardized seropositive individuals

⁴Confidence intervals (CI) were estimated according to Wilson-Score-Method

⁵Confidence intervals (CI) were computed as Bayesian credibility intervals (see methods)

Supplemental Table 6: Symptoms by serostatus. Shown are relative (%) and absolute (#) frequencies of reported symptoms by participants per serostatus subgroup (column) with a corresponding [number of participants with non-missing information]. In addition, we show the Odds Ratio, OR, with associated 95%-CI comparing serostatus positive versus serostatus negative (unadjusted; results adjusted for age and sex very similar, data not shown). Participants have been asked whether they had experienced any of the stated symptoms since the start of the pandemic (as per Feb 1st, 2020).

	Serostatus positive AND PCR-test pos	Serostatus positive AND no PCR-test or neg.	Serostatus positive	Serostatus negative	OR (95%-CI)
Coughing, % (#)	66.7 (46) [n=69]	41.2 (121) [n=294]	46.0 (167) [n=363]	30.0 (1139) [n=3799]	1.99 [1.6, 2.47]
Shortness of Breath, % (#)	33.3 (23) [n=69]	10.2 (30) [n=294]	14.6 (53) [n=363]	5.8 (220) [n=3799]	2.78 [2.02, 3.84]
Breathing problems, % (#)	39.1 (27) [n=69]	18.0 (53) [n=294]	22.0 (80) [n=363]	9.2 (351) [n=3799]	2.78 [2.12, 3.64]
Fever, % (#)	55.1 (38) [n=69]	30.3 (89) [n=294]	35.0 (127) [n=363]	7.6 (289) [n=3799]	6.54 [5.11, 8.37]
Chills, % (#)	34.8 (24) [n=69]	20.7 (61) [n=294]	23.4 (85) [n=363]	6.5 (248) [n=3799]	4.38 [3.33, 5.76]
Pain in extremities, % (#)	50.7 (35) [n=69]	37.1 (109) [n=294]	39.7 (144) [n=363]	18.1 (689) [n=3799]	2.97 [2.37, 3.72]
Diarrhea, % (#)	37.7 (26) [n=69]	21.8 (64) [n=294]	24.8 (90) [n=363]	17.6 (669) [n=3799]	1.54 [1.2, 1.99]
Olfactory problems, % (#)	58.0 (40) [n=69]	32.7 (96) [n=294]	37.5 (136) [n=363]	2.7 (101) [n=3799]	21.94 [16.41, 29.32]
Taste problems, % (#)	63.8 (44) [n=69]	35.4 (104) [n=294]	40.8 (148) [n=363]	4.1 (155) [n=3799]	16.18 [12.43, 21.07]
Nausea, % (#)	17.4 (12) [n=69]	12.6 (37) [n=294]	13.5 (49) [n=363]	8.3 (314) [n=3799]	1.73 [1.25, 2.39]
Eye inflammation, % (#)	8.7 (6) [n=69]	4.1 (12) [n=294]	5.0 (18) [n=363]	5.3 (200) [n=3799]	0.94 [0.57, 1.54]
Headache, % (#)	42.0 (29) [n=69]	35.7 (105) [n=294]	36.9 (134) [n=363]	33.1 (1259) [n=3799]	1.18 [0.94, 1.48]
Fatigue, % (#)	75.4 (52) [n=69]	53.1 (156) [n=294]	57.3 (208) [n=363]	29.1 (1104) [n=3799]	3.28 [2.63, 4.08]
Rhinitis, % (#)	27.5 (19) [n=69]	35.0 (103) [n=294]	33.6 (122) [n=363]	27.8 (1056) [n=3799]	1.31 [1.05, 1.65]
Nothing of the above, % (#)	2.9 (2) [n=69]	15.3 (45) [n=294]	12.9 (47) [n=363]	35.6 (1353) [n=3799]	0.27 [0.2, 0.37]

Supplemental Table 7: Reported symptoms by sex and age groups. Shown are relative (%) and absolute (#) frequencies of individuals reporting symptoms from a subgroup-specific [number of individuals with non-missing information]. Participants have been asked whether they had experienced any of the stated symptoms since the start of the pandemic (as per Feb 1st, 2020).

	All	Male	Female	Age 14-19	Age 20-69	Age >=70
Coughing, % (#)	31.4 (1307) [n=4164]	32.2 (650) [n=2016]	30.6 (657) [n=2148]	37.9 (86) [n=227]	32.6 (1082) [n=3316]	22.4 (139) [n=621]
Shortness of Breath, % (#)	6.6 (273) [n=4164]	5.6 (113) [n=2016]	7.4 (160) [n=2148]	3.1 (7) [n=227]	6.2 (205) [n=3316]	9.8 (61) [n=621]
Breathing problems, % (#)	10.4 (431) [n=4164]	10.0 (201) [n=2016]	10.7 (230) [n=2148]	6.2 (14) [n=227]	10.7 (356) [n=3316]	9.8 (61) [n=621]
Fever, % (#)	10.0 (417) [n=4164]	9.2 (186) [n=2016]	10.8 (231) [n=2148]	15.9 (36) [n=227]	10.4 (344) [n=3316]	6.0 (37) [n=621]
Chills, % (#)	8.0 (334) [n=4164]	6.7 (136) [n=2016]	9.2 (198) [n=2148]	7.5 (17) [n=227]	8.9 (295) [n=3316]	3.5 (22) [n=621]
Pain in extremities, % (#)	20.0 (834) [n=4164]	19.1 (386) [n=2016]	20.9 (448) [n=2148]	13.2 (30) [n=227]	20.7 (688) [n=3316]	18.7 (116) [n=621]
Diarrhea, % (#)	18.2 (759) [n=4164]	18.1 (364) [n=2016]	18.4 (395) [n=2148]	17.2 (39) [n=227]	19.6 (651) [n=3316]	11.1 (69) [n=621]
Olfactory problems, % (#)	5.7 (237) [n=4164]	4.7 (95) [n=2016]	6.6 (142) [n=2148]	3.1 (7) [n=227]	6.1 (202) [n=3316]	4.5 (28) [n=621]
Taste problems, % (#)	7.3 (303) [n=4164]	6.5 (132) [n=2016]	8.0 (171) [n=2148]	4.0 (9) [n=227]	8.0 (264) [n=3316]	4.8 (30) [n=621]
Nausea, % (#)	8.7 (364) [n=4164]	5.8 (116) [n=2016]	11.5 (248) [n=2148]	11.9 (27) [n=227]	9.3 (307) [n=3316]	4.8 (30) [n=621]
Eye inflammation, % (#)	5.2 (218) [n=4164]	4.7 (94) [n=2016]	5.8 (124) [n=2148]	2.6 (6) [n=227]	5.3 (175) [n=3316]	6.0 (37) [n=621]
Headache, % (#)	33.5 (1394) [n=4164]	26.6 (536) [n=2016]	39.9 (858) [n=2148]	42.7 (97) [n=227]	37.2 (1232) [n=3316]	10.5 (65) [n=621]
Fatigue, % (#)	31.5 (1313) [n=4164]	27.4 (552) [n=2016]	35.4 (761) [n=2148]	23.3 (53) [n=227]	33.7 (1117) [n=3316]	23.0 (143) [n=621]
Rhinitis, % (#)	28.3 (1179) [n=4164]	29.9 (602) [n=2016]	26.9 (577) [n=2148]	40.5 (92) [n=227]	30.1 (999) [n=3316]	14.2 (88) [n=621]
Nothing, % (#)	33.6 (1401) [n=4164]	35.4 (713) [n=2016]	32.0 (688) [n=2148]	27.8 (63) [n=227]	31.0 (1027) [n=3316]	50.1 (311) [n=621]

Supplemental Table 8: Association of demographic and lifestyle factors with seropositivity.

Shown are Odds Ratios (OR) and 95%-confidence intervals as well as P-values from three logistic regression models. Participants were asked in which profession they were mostly working in February 2020, whether and how much they were smoking and drinking alcohol at the time of the questionnaire completion (from June 19th, 10 days prior to 1st day of the blood draws, until the last day of the blood draws), which was 1-3 weeks before the blood draw to derive serum antibody status. Body-mass-index was derived from self-reported weight and height in the questionnaire and physical activity was assessed as any of category of ≥ 1 hours per week (medium/high) versus < 1 hours per week (including walking and biking). CI = confidence interval

Covariate [reference]	Cat	Model I			Model II			Model III					
		OR	95%-CI	P	OR	95%-CI	P	OR	95%-CI	P			
Intercept*		0.09	0.07	0.10	-	0.08	0.05	0.11	-	0.09	0.05	0.14	-
Age [20-69]	14-19	1.20	0.75	1.84	0.422	1.20	0.72	1.92	0.463	1.24	0.72	2.05	0.427
	70+	0.95	0.69	1.28	0.740	1.06	0.73	1.50	0.750	0.95	0.65	1.38	0.799
Sex [male]	female	1.02	0.82	1.26	0.871	0.93	0.73	1.17	0.519	1.02	0.78	1.32	0.906
Education years [6-10]	11-15	-	-	-	-	1.07	0.84	1.37	0.582	0.96	0.75	1.25	0.775
	16-23	-	-	-	-	0.94	0.6	1.43	0.771	0.85	0.54	1.31	0.481
Person household [1]	2	-	-	-	-	0.89	0.62	1.32	0.565	0.87	0.59	1.31	0.482
	3-5	-	-	-	-	1.05	0.73	1.55	0.793	0.99	0.67	1.49	0.963
	6+	-	-	-	-	1.05	0.58	1.85	0.860	0.96	0.52	1.73	0.902
Profession [other]	grocery	-	-	-	-	0.87	0.36	1.77	0.725	0.82	0.31	1.76	0.637
	medicine	-	-	-	-	2.13	1.46	3.07	<0.001	2.26	1.53	3.28	<0.001
Phys. Activity [high]	low	-	-	-	-	-	-	-	-	0.93	0.71	1.21	0.577
Alcohol drinks / day [0-0.25]	0	-	-	-	-	-	-	-	-	0.76	0.52	1.09	0.144
	0.25-1	-	-	-	-	-	-	-	-	1.28	0.95	1.72	0.101
	>1	-	-	-	-	-	-	-	-	1.33	0.96	1.85	0.860
BMI [18.5-25]	<18.5	-	-	-	-	-	-	-	-	1.16	0.39	2.80	0.760
	25-30	-	-	-	-	-	-	-	-	1.14	0.86	1.50	0.367
	>30	-	-	-	-	-	-	-	-	1.05	0.76	1.43	0.781
Smoking [never]	ex	-	-	-	-	-	-	-	-	0.97	0.74	1.27	0.843
	current	-	-	-	-	-	-	-	-	0.36	0.24	0.53	<0.001

* Intercept corresponds to estimated probability of seropositivity in reference categories

Follow-up analysis on the smoking finding:

Supplemental Table 9: Odds-ratios and corresponding 95%-CIs (Wald) by age-groups and sex (current smoking vs. serostatus positive), young=14-39, middle age=40-59, old >=60

Group		n	# pos	# smoke	% pos. smoke	% pos. non-smoke	OR	95%-CI
Overall		4176	363	852	4.2	9.8	0.404	[0.284, 0.575]
Age-group	young	1332	105	297	4.0	9.0	0.426	[0.230, 0.789]
	mid	1476	146	370	4.3	11.8	0.339	[0.199, 0.578]
	old	1368	112	185	4.3	8.8	0.469	[0.225, 0.979]
Sex	male	2021	174	441	3.4	10.1	0.315	[0.183, 0.540]
	female	2155	189	411	5.1	9.6	0.505	[0.317, 0.806]
Age x Sex	young, male	650	41	163	3.1	7.4	0.396	[0.153, 1.028]
	young, female	682	64	134	5.2	10.4	0.475	[0.211, 1.066]
	mid, male	721	76	185	2.7	13.2	0.182	[0.072, 0.458]
	mid, female	755	70	185	5.9	10.4	0.548	[0.281, 1.066]
	old, male	650	57	93	5.4	9.3	0.552	[0.214, 1.420]
	old, female	718	55	92	3.3	8.3	0.372	[0.114, 1.217]

Supplemental Table 10. Odds-ratios and corresponding 95%-CIs (Wald) by age-sex group (current smoking vs. PCR-test positive if tested), young=14-39, middle age=40-59, old >=60


Group		n	# pos	# smoke	% pos. smoke	% pos. non-smoke	OR	95%-CI
Overall		501	74	105	6.7	16.9	0.351	[0.156, 0.789]
Age-group	young	145	16	34	2.9	13.5	0.194	[0.025, 1.525]
	mid	216	30	58	5.2	17.1	0.265	[0.077, 0.909]
	old	140	28	13	23.1	19.7	1.224	[0.313, 4.780]
Sex	male	190	39	31	9.7	22.6	0.366	[0.105, 1.274]
	female	311	35	74	5.4	13.1	0.38	[0.129, 1.114]
Age x Sex	young, male	49	7	11	0	18.4	0	-
	young, female	96	9	23	4.3	11.0	0.369	[0.044, 3.120]
	mid, male	74	13	14	7.1	20.0	0.308	[0.037, 2.589]
	mid, female	142	17	44	4.5	15.3	0.263	[0.058, 1.206]
	old, male	67	19	6	33.3	27.9	1.294	[0.217, 7.730]
	old, female	73	9	7	14.3	12.1	1.208	[0.128, 11.377]

Supplemental Table 11: Dose-response models for seropositivity versus seronegativity. Shown are results from logistic regression modeling a linear effect of the number of smoked cigarettes on the binary outcome.

All participants (Non-smokers with 0 cigarettes per day)					
Covariate [reference]	Cat	OR	95%-CI		P
Intercept*		0.10	0.08	0.11	-
Age [20-69]	14-19	1.07	0.67	1.64	0.773
	70+	0.85	0.62	1.15	0.317
Sex [male]	female	0.99	0.80	1.23	0.926
#Cigs	(per 10)	0.50	0.37	0.65	<0.001

Current smoker					
Covariate [reference]	Cat	OR	95%-CI		P
Intercept*		0.05	0.02	0.10	-
Age [20-69]	14-19	1.70	0.26	6.51	0.501
	70+	1.68	0.39	5.01	0.411
Sex [male]	female	1.46	0.74	2.93	0.281
#Cigs	(per 10)	0.69	0.43	1.07	0.108

* Intercept corresponds to estimated probability of seropositivity in reference categories




Supplemental Figure 1

Supplemental Figure 2

Nonlinear effect number of cigarettes

All ($p < 0.001$)



Legends to Supplemental Figures

Supplemental Figure 1 Proportion (%) of TiKoCo-19 study participants versus county population in the various age groups.

Figure was designed using GraphPad Prism version 8.4.3 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com

Supplemental Figure 2 Non-linear association of number of cigarettes with seropositivity. Log-OR are shown for all participants and active smokers. P-values are indicated.

Analysis was conducted in R (R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <http://www.R-project.org/>) and figure 2 was produced using the package ggplot2 (Wickham, H. (2009) ggplot2: elegant graphics for data analysis. Springer New York).